M
Matija Tomšič
Researcher at University of Ljubljana
Publications - 196
Citations - 3973
Matija Tomšič is an academic researcher from University of Ljubljana. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 28, co-authored 163 publications receiving 3285 citations. Previous affiliations of Matija Tomšič include Academy of Sciences of the Czech Republic & Ljubljana University Medical Centre.
Papers
More filters
Journal ArticleDOI
Op0143 predictors of severe cranial ischemic complications in giant cell arteritis
TL;DR: Conventional cardiovascular risk factors (obesity, arterial hypertension, hyperlipidemia, diabetes mellitus, and smoking were not associated with severe cranial ischemic complications and there were no significant differences in the median level of C-reactive protein or haemoglobin concentration between the compared groups.
Assessment oftheEuropean classification criteria forSjogren's syndrome inaseries ofclinically defined cases: results ofaprospective multicentre study
Claudio Vitali,Stefano Bombardieri,Haralampos M Moutsopoulos,J Coll,Roberto Gerli,Louis Kater,Olivier Meyer,Pierantonio Ostuni,Andrea Richards,Bernard Sauvezie,Fotini N Skopouli,Josef SSmolen,Francisco Soromenho,Matija Tomšič,Christine M Yeoman +14 more
TL;DR: This prospective study confirmed the highvalidity andreliability of the preliminary criteria for Sjogren's syndrome recently proposed by the EuropeanCommunity StudyGroup.
Journal ArticleDOI
POS1548 ENTHESITIS OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS INITIATING A TUMOUR NECROSIS FACTOR INHIBITOR IN A REAL-WORLD SETTING: DATA FROM THE EuroSpA COLLABORATION NETWORK
Ann Mathew,L. Midtbøll Ørnbjerg,Marie Pedersen,Stylianos Georgiadis,Bente Glintborg,A. Loft,M J Nissen,B. Moeller,Ana M. Rodrigues,F. Pimentel-Santos,Ziga Rotar,Matija Tomšič,Heikki Relas,Ritva Peltomaa,Bjorn Gudbjornsson,T. Löve,Sinem Burcu Kocaer,Aydan Köken Avşar,M.L. Hetland,M. Østergaard +19 more
TL;DR: In this paper , the impact of tumor necrosis factor inhibitors (TNFi) on enthesitis in patients with psoriatic arthritis (PsA) in the EuroSpA collaboration network was explored.
Journal ArticleDOI
POS0077 SEX DIFFERENCES IN EFFECTIVENESS OF FIRST-LINE TUMOR NECROSIS FACTOR INHIBITORS IN PSORIATIC ARTHRITIS; RESULTS FROM THIRTEEN COUNTRIES IN THE EuroSpA RESEARCH COLLABORATION NETWORK
P. Hellamand,Marleen G H van de Sande,L. Midtbøll Ørnbjerg,Thomas Klausch,Nina Trokovic,T. Sokka-Isler,M J Parreira Santos,Elsa Vieira-Sousa,A. Loft,Bente Glintborg,Mette Østergaard,Ulf Lindström,J Wallman,Brigitte Michelsen,B. Moeller,Raphael Micheroli,Catalin Codreanu,Corina Mogosan,K Laas,Ziga Rotar,K. Fagerli,Matija Tomšič,Isabel Castrejón,Manuel Pombo-Suarez,Bjorn Gudbjornsson,T. Love,Karel Pavelka,Jakub Zavada,Gökçe Kenar,Handan Yarkan-Tuğsal,M.L. Hetland,I. van der Horst-Bruinsma +31 more
TL;DR: To investigate sex differences in treatment response and drug retention rates in clinical practice among patients with PsA, treated with their first TNFi, data from biologic-naïve PsA patients initiating a TNFi in the EuroSpA registries were pooled.